Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive a ...

Group 1 - The company has made significant progress in clinical trials, particularly with the Phase II MASH trial, which provided data at both 24 weeks and 48 weeks [2] - The 48-week data set reinforces expectations for the upcoming Phase III trial design for pemvidutide in MASH [2] - The company anticipates an exciting year ahead in 2026, indicating ongoing developments and potential advancements [2]

Summary of Altimmune's Conference Call Company Overview - **Company**: Altimmune - **Key Executives Present**: Jerry Durso (CEO), Christophe Arbet-Engels (CMO), Greg Weaver (CFO) [1][2] Industry and Product Focus - **Industry**: Biotech, specifically focusing on liver diseases such as Metabolic Associated Steatotic Hepatitis (MASH), Alcohol Use Disorder (AUD), and Alcohol-Associated Liver Disease (ALD) - **Key Product**: Pemvidutide, a dual-action drug targeting glucagon and GLP-1 receptors [4][12] Key Highlights and Core Points Clinical Progress - **MASH Trials**: Significant progress in the Phase 2 MASH trial with 24-week and 48-week data showing potential for pemvidutide as a differentiated product in the MASH space [4][5] - **AUD Trials**: Enrollment ahead of schedule with top-line data expected in Q3 2026 [8] - **ALD Trials**: Enrollment expected to complete this year with two main readouts at 24 weeks and 48 weeks [43] Financial Position - **Balance Sheet**: Focus on strengthening the balance sheet through a combination of debt and equity, with discussions ongoing with strategic partners [6] - **Capital Allocation**: Emphasis on ensuring sufficient capital for the Phase 3 trial initiation [6] Differentiation of Pemvidutide - **Mechanism of Action**: Unique one-to-one ratio of glucagon and GLP-1, showing strong effects on fibrosis and MASH resolution [12] - **Tolerability**: Lower discontinuation rates compared to competitors, with a focus on preserving lean mass during weight loss [12][13] - **Data Insights**: Positive 48-week data indicating a clear dose response and strong anti-fibrotic effects [19] Phase 3 Trial Design - **Trial Structure**: Three arms including placebo and two doses (1.8 mg and 2.4 mg), with a focus on good tolerability observed in Phase 2 [22] - **Use of AIM-MASH AI Assist**: A novel tool to reduce variability in histology readings and improve objectivity in trial outcomes [26][29] Regulatory Considerations - **FDA Discussions**: Ongoing discussions with the FDA regarding the use of non-invasive tests (NITs) as endpoints, with current data being captured for potential future discussions [35] Market Potential - **AUD Population**: Estimated 12 million individuals in the AUD category, with a significant unmet need for effective treatments [50] - **Pricing Strategy**: Anticipation of different pricing strategies for MASH and AUD therapies, with a focus on differentiation and value [52][53] Additional Insights - **Enrollment Timelines**: Expectation to complete enrollment for trials within 18-24 months, leveraging strong site relationships and previous trial learnings [38] - **Patient-Reported Outcomes**: Emphasis on capturing both subjective and objective measures of treatment efficacy in AUD trials [40][41] Conclusion - Altimmune is positioned for a significant year ahead with multiple ongoing trials and a focus on innovative treatment approaches for liver diseases, particularly through the development of pemvidutide. The company is actively working on strengthening its financial position and preparing for Phase 3 trials while engaging with regulatory bodies to optimize trial outcomes and market entry strategies.

Summary of Altimmune Conference Call Company Overview - **Company**: Altimmune - **Event**: Leerink Partners Global Healthcare Conference - **Key Participants**: CEO Jerry Durso, CMO Christophe Arbet-Engels, CFO Greg Weaver Industry Focus - **Primary Focus**: MASH (Metabolic Associated Steatotic Liver Disease) - **Clinical Trials**: Phase 2 and Phase 3 trials for pemvidutide, a treatment for MASH and other liver-related diseases Key Points and Arguments Clinical Data and Regulatory Progress - **2025 Highlights**: Significant clinical data expected, including two readouts from the Phase 2 MASH trial in 2025, with 24-week and 48-week data showing promising results for pemvidutide [6][18] - **Regulatory Feedback**: Received breakthrough therapy designation from the FDA, indicating strong alignment on Phase 3 trial design [6][34] - **Phase 3 Trial**: Focus on a 52-week endpoint to assess antifibrotic effects, with a simple titration scheme for dosing to improve tolerability [20][27] Pemvidutide Differentiation - **Mechanism of Action**: Pemvidutide combines glucagon and GLP-1 in a 1:1 ratio, which is believed to provide a balanced therapeutic effect, unlike competitors like survodutide, which has a 7:1 ratio favoring GLP-1 [10][12] - **Tolerability**: Pemvidutide shows lower discontinuation rates compared to other treatments, with less than placebo rates of discontinuation [13][33] - **Efficacy**: Strong indications of antifibrotic effects observed in non-invasive tests, with confidence in achieving significant results in the upcoming Phase 3 trial [18][19] Market Position and Strategy - **Patient Segmentation**: Physicians are expected to segment patients based on tolerability and efficacy, with pemvidutide positioned as a favorable option for patients who struggle with other incretin therapies [63][64] - **Combination Therapy Potential**: Pemvidutide may serve as a complementary agent in combination therapies, enhancing efficacy without increasing side effects [58][59] Upcoming Trials and Endpoints - **Alcohol Use Disorder (AUD) and Alcohol-Related Liver Disease (ALD)**: Two unique Phase 2 programs are underway, targeting large unmet needs in these areas [67][68] - **Endpoints for AUD**: Focus on reducing heavy drinking days, with a target of a 1-day reduction in average heavy drinking days as a meaningful clinical outcome [75][77] Regulatory Considerations - **FDA Engagement**: Ongoing discussions with the FDA regarding the use of non-invasive tests (NITs) for regulatory approval, with potential for evolving acceptance during the trial [42][46] - **Global Alignment**: Efforts to align with European regulatory bodies (EMA, MHRA) to ensure a cohesive global strategy for pemvidutide [51] Additional Important Insights - **Long-term Market Outlook**: The MASH market is expected to evolve similarly to the diabetes market, with multiple mechanisms and treatment options becoming available [65] - **Focus on F4 Population**: While the primary focus remains on F2 and F3 populations, there is potential for future exploration in the F4 compensated cirrhotic population [54] This summary encapsulates the critical insights and strategic directions discussed during the Altimmune conference call, highlighting the company's focus on advancing pemvidutide as a leading treatment option in the MASH and liver disease landscape.

Summary of Altimmune Conference Call Company Overview - **Company**: Altimmune (NasdaqGM:ALT) - **Event**: Citizens Life Sciences Conference on March 10, 2026 - **Key Speakers**: Jerry Durso (CEO), Linda Richardson (Chief Commercial Officer), Greg Weaver (CFO) Core Industry and Product Insights - **Lead Product**: Pemvidutide, targeting multiple liver indications, primarily MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) [4][5] - **Phase 2 Trials**: - Positive results from 24-week and 48-week readouts, showing significant impact on MASH resolution and good tolerability [6][10] - Weight loss and trends on fibrosis were noted, although the fibrosis endpoint was not met due to a high placebo response [7][14] - **Phase 3 Trial Plans**: - Anticipated initiation in 2026 with a focus on a 52-week endpoint and a cohort of nearly 1,000 patients [9][18] - Inclusion of a titration scheme to improve tolerability and patient retention [12][26] Mechanism of Action - **Dual Mechanism**: Pemvidutide combines glucagon and GLP-1 in a 1:1 ratio, aiming to address both liver fat reduction and metabolic effects [28][29] - **Differentiation**: The one-to-one ratio is believed to enhance tolerability and efficacy compared to other glucagon/GLP-1 combinations [29][41] Market Position and Competitive Landscape - **Market Need**: High unmet need in the MASH space, with increasing recognition from physicians and payers [56][60] - **Competitors**: Other GLP-1 therapies and FGF21s are noted, with pemvidutide expected to have a competitive edge due to its unique profile [62][53] - **Commercial Strategy**: Focus on maintaining tolerability and addressing weight loss, which is critical for MASH patients [38][61] Financial Position - **Cash Position**: Strong balance sheet with a runway into 2028, having raised approximately $300 million over the past year [78] - **Strategic Funding**: Open to potential partnerships, especially for ex-US markets [79] Additional Insights - **Alcohol Use Disorder (AUD) and Alcohol-Related Liver Disease (ALD)**: Ongoing studies with anticipated readouts in 2026, highlighting the potential of pemvidutide in these areas [66][67] - **Market Research**: Indications that current therapies are not meeting weight loss needs, positioning pemvidutide favorably [60][61] Conclusion - Altimmune is poised to advance pemvidutide through its upcoming phase 3 trials, with a strong focus on addressing the significant unmet needs in liver disease management and maintaining a competitive edge in the evolving therapeutic landscape. The company is actively preparing for commercialization while ensuring a robust financial foundation to support its initiatives.

Core Insights - The CEO of Altimmune, Durso Jerome Benedict, purchased 20,000 shares at approximately $3.54 per share, increasing his total holdings to 32,500 shares, indicating strong confidence in the company's future [1][5] - Altimmune is preparing for a pivotal Phase 3 program for pemvidutide, targeting metabolic dysfunction-associated steatohepatitis (MASH), which aligns with the company's strategic focus on liver disease treatments [2][5] - The unique approach of pemvidutide, featuring "balanced one-to-one agonism of glucagon and GLP-1," may differentiate Altimmune in the treatment landscape, potentially reducing liver fat and aiding in weight loss [3][5] Financial Overview - The current stock price of ALT is $3.54, with a slight increase of 0.99% or $0.035, and has fluctuated between $3.41 and $3.74 throughout the day [4] - Over the past year, ALT reached a high of $7.73 and a low of $2.9, with a market capitalization of approximately $312.4 million and a trading volume of 5,385,353 shares [4]

Financial Performance - Altimmune reported a 105% increase in revenue for the year ended December 31, 2025, totaling $41,000 compared to $20,000 in 2024[500]. - The net loss for the year ended December 31, 2025, was $88,093,000, a decrease of 7% from the net loss of $95,059,000 in 2024[500]. - Total other income (expense), net decreased by $2.4 million in 2025, primarily due to increased interest expense related to a Term Loan[505]. - The accumulated deficit reached $649.5 million as of December 31, 2025, with no revenues generated from product sales to date[508]. Research and Development - Research and development expenses decreased by 19% to $66,432,000 in 2025 from $82,226,000 in 2024, primarily due to the completion of the IMPACT Phase 2b trial for MASH[500][502]. - Altimmune plans to increase research and development expenses in the future to support ongoing clinical trials for pemvidutide in MASH, AUD, and ALD[495]. - The company is pursuing additional indications for pemvidutide, specifically for AUD and ALD, with trials currently underway[482][487]. - The company announced positive 48-week topline results from the IMPACT Phase 2b trial, showing significant improvements in anti-fibrosis NITs[481]. Clinical Trials - The company completed enrollment in the RECLAIM Phase 2 trial for AUD ahead of schedule, targeting approximately 100 subjects[486]. - The FDA granted Fast Track designation to pemvidutide for the treatment of AUD, aimed at expediting its development[484]. Cash Flow and Financing - As of December 31, 2025, the company had cash, cash equivalents, restricted cash, and short-term investments totaling $273.5 million[507]. - Net cash used in operating activities decreased to $67.5 million in 2025 from $79.8 million in 2024, reflecting a $12.3 million improvement[519]. - Net cash used in investing activities was $132.5 million in 2025, primarily due to a $285.4 million purchase of short-term investments[520]. - Net cash provided by financing activities increased significantly to $206.8 million in 2025, compared to $10.0 million in 2024[521]. - The company entered into a Loan and Security Agreement with Hercules Capital, allowing for up to $125.0 million in term loans, with the first two tranches totaling $35.0 million drawn down[509][510]. - The company filed a shelf registration statement allowing for the sale of up to $400.0 million of various securities, effective for three years[512]. - The company raised approximately $25.4 million in net proceeds from at-the-market offerings since inception through December 31, 2025, with $174.2 million remaining available[514]. - The company plans to continue pursuing additional equity or debt financing to address long-term capital needs, particularly for clinical trials[523]. Stock Compensation and Market Risk - The company has incurred significant research and development costs, which are expensed as incurred, impacting cash flow and capital resources[526]. - The company acknowledges a high degree of subjectivity in using option pricing models for estimating stock-based compensation, which may lead to significant differences in future compensation expenses compared to historical reports[533]. - As a "smaller reporting company," the company is not required to provide detailed market risk disclosures as per Item 7A of Regulation S-K[534].

Financial Data and Key Metrics Changes - The net loss for Q4 2025 was $27.4 million or $0.27 per share, compared to a net loss of $23.2 million or $0.33 per share in Q4 2024 [31][32] - R&D expenses in Q4 2025 were $18.4 million, down from $19.8 million in the same period of 2024, primarily due to the end of the phase 2b trial [30] - G&A expenses increased to $10.5 million in Q4 2025 from $5.1 million in Q4 2024, driven by a one-time charge related to executive transition [31] Business Line Data and Key Metrics Changes - The company is focused on advancing pemvidutide for liver diseases, particularly MASH, with promising results from phase 2 trials indicating strong therapeutic potential [6][9] - The phase 2 MASH study showed early resolution at 24 weeks and anti-fibrotic activity at 48 weeks, with significant improvements in liver fat and inflammation markers [9][17] Market Data and Key Metrics Changes - Market research indicated a high unmet need for therapies addressing tolerability issues in MASH patients, with many physicians seeking alternatives to existing treatments [25][26] - Over 70% of healthcare professionals surveyed expressed a high likelihood of prescribing pemvidutide, indicating strong market interest [28] Company Strategy and Development Direction - The company aims to strengthen its foundation for the advancement of pemvidutide and has enhanced its leadership team with expertise in liver disease and clinical development [11] - The phase 3 trial for pemvidutide is set to begin this year, with a focus on addressing both hepatic and metabolic drivers of MASH [20][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pemvidutide, especially after receiving FDA Breakthrough Therapy designation for MASH [10] - The company is preparing for the phase 3 trial while ensuring financial stability, with a cash position of approximately $340 million expected to support operations into 2028 [33][34] Other Important Information - The company has received valuable guidance from the FDA regarding the phase 3 trial design, which will include both biopsy-confirmed and non-invasive test cohorts [20][22] - The phase 2 trials for AUD and ALD are progressing well, with top-line data expected from the AUD trial in Q3 2026 [23][24] Q&A Session Summary Question: Can the FDA's new single pivotal framework save costs for the phase 3 trial? - Management indicated that the current approach remains unchanged and the single trial path for accelerated approval is still valid [38] Question: What are the statistical plans for the phase 3 trial? - The phase 3 trial is powered for two primary endpoints, with a sample size of around 990 patients, ensuring sufficient power for approval [41] Question: What is the FDA's stance on using non-invasive tests as registrational endpoints? - The FDA deemed it premature to consider non-invasive tests for approval, focusing instead on biopsy-driven endpoints [48] Question: What are the key elements locked in for the phase 3 protocol? - The protocol is nearing finalization, with critical elements like sample size and primary endpoints aligned, while ensuring comprehensive biopsy processes [85] Question: How will the company approach the AUD and ALD trials? - The company plans to assess AUD data and make decisions without waiting for ALD results, focusing on immediate next steps [93]

Financial Data and Key Metrics Changes - The net loss for Q4 2025 was $27.4 million or $0.27 per share, compared to a net loss of $23.2 million or $0.33 per share in Q4 2024, indicating an increase in losses year-over-year [31][32] - R&D expenses in Q4 2025 were $18.4 million, down from $19.8 million in the same period of 2024, primarily due to the completion of the Phase 2b trial [30] - G&A expenses increased to $10.5 million in Q4 2025 from $5.1 million in Q4 2024, driven by one-time charges related to executive transition and increased professional fees [31] Business Line Data and Key Metrics Changes - The company is focused on advancing pemvidutide for liver diseases, particularly MASH, with promising results from Phase 2 trials showing early MASH resolution and anti-fibrotic activity [9][16] - The Phase 2 AUD trial completed enrollment ahead of schedule, with top-line data expected in Q3 2026 [14][23] - The Phase 2 trial assessing pemvidutide in ALD is expected to complete enrollment in 2026 [14] Market Data and Key Metrics Changes - Market research indicated significant unmet needs among MASH patients, particularly for those who have discontinued semaglutide due to tolerability issues [25][26] - Physicians expressed a high unmet need for therapies that preserve lean muscle mass in MASH patients, highlighting the potential competitive advantage of pemvidutide [25][26] Company Strategy and Development Direction - The company aims to strengthen its foundation for the advancement of pemvidutide and has enhanced its leadership team with expertise in liver disease and late-stage clinical development [11] - A $75 million capital raise was completed to support the planned initiation of the Phase 3 trial for pemvidutide [12] - The company is preparing for a pivotal Phase 3 trial with a focus on MASH, aligning with FDA guidance on trial design and endpoints [20][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pemvidutide to address significant unmet needs in liver diseases, emphasizing its dual mechanism of action [6][9] - The company is committed to creating long-term value for shareholders while advancing its clinical programs [35] Other Important Information - The company reported total cash of $274 million at year-end 2025, with a pro forma cash position of approximately $340 million after recent capital raises [32][33] - The Phase 3 trial will enroll approximately 1,800 patients globally, with a focus on both biopsy-confirmed and non-invasive test-assessed MASH patients [21][22] Q&A Session Summary Question: Can the FDA's new single pivotal framework save costs for the Phase 3 trial? - Management indicated that the current approach remains unchanged and the path for approval is through a single trial for accelerated approval [36][38] Question: What are the statistical plans for the Phase 3 trial? - The study is powered for two primary endpoints, with a sample size of around 990 patients, ensuring sufficient power for approval [39][41] Question: What is the FDA's stance on using non-invasive tests as registrational endpoints? - The FDA deemed it premature to consider non-invasive tests for approval, focusing instead on biopsy-driven endpoints [47][48] Question: What are the key elements locked in for the Phase 3 protocol? - The protocol is nearing finalization, with critical elements like sample size and primary endpoints aligned, while finalizing biopsy details [86][87] Question: How will the company proceed with the AUD and ALD trials? - The company plans to assess AUD data and make decisions without waiting for ALD results, focusing on immediate next steps [93]

Financial Data and Key Metrics Changes - The net loss for Q4 2025 was $27.4 million or $0.27 per share, compared to a net loss of $23.2 million or $0.33 per share in Q4 2024, indicating an increase in losses year-over-year [31] - R&D expenses in Q4 2025 were $18.4 million, down from $19.8 million in the same period of 2024, primarily due to the completion of the Phase 2b trial [30] - G&A expenses increased to $10.5 million in Q4 2025 from $5.1 million in Q4 2024, driven by a one-time charge related to executive transition and increased professional fees [31] Business Line Data and Key Metrics Changes - The company is focused on advancing pemvidutide for liver diseases, particularly MASH, with promising results from Phase 2 trials showing early MASH resolution and anti-fibrotic activity [8][14] - The Phase 2 MASH study demonstrated significant improvements in liver fat content and liver health markers, with a favorable tolerability profile leading to low discontinuation rates [16][17] Market Data and Key Metrics Changes - Market research indicated a high unmet need for therapies addressing tolerability issues in MASH patients, with many physicians recognizing the limitations of current therapies [24][25] - Over 70% of healthcare professionals surveyed expressed a high likelihood to prescribe pemvidutide, indicating strong market interest [27] Company Strategy and Development Direction - The company aims to strengthen its foundation for the advancement of pemvidutide and has enhanced its leadership team with expertise in liver disease and late-stage clinical development [10] - The Phase 3 trial for pemvidutide is set to begin this year, with a focus on addressing both hepatic and metabolic drivers of MASH [19][20] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of pemvidutide, especially after receiving FDA Breakthrough Therapy designation, which could facilitate its approval process [9] - The company is preparing for the Phase 3 trial while also executing well on other Phase 2 trials, indicating a robust pipeline and commitment to addressing liver diseases [12][20] Other Important Information - The company raised $75 million in a capital raise in January 2026, enhancing its financial position to support ongoing clinical programs [11][33] - The total cash position at year-end 2025 was reported at $274 million, with a pro forma cash position of approximately $340 million after recent funding [33] Q&A Session Summary Question: Can you provide insights on the Phase 3 trial and potential cost savings? - Management clarified that the FDA's new pivotal framework does not directly apply to their approach, and they are focused on a single trial for accelerated approval [38] Question: What are the statistical plans for the Phase 3 trial? - The Phase 3 trial is powered for two primary endpoints, with a sample size of around 990 patients, ensuring sufficient power for approval [41] Question: What is the FDA's stance on using NIT as a registrational endpoint? - The FDA indicated it was premature to consider NITs as registrational endpoints, but the company is capturing all relevant data [49] Question: What are the key elements locked in for the Phase 3 protocol? - The protocol is nearing finalization, with critical elements like sample size and primary endpoints aligned, focusing on comprehensive biopsy processes [87] Question: How will the company approach the AUD and ALD trials? - The company plans to assess the AUD trial data upon receipt and will not wait for ALD data before determining next steps [94]